Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

11.71 -0.04 (-0.38%)
Streaming Delayed Price Updated: 2:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. - Common Stock

< Previous 1 2 3 Next >
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
Via Investor Brand Network
News headline image
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
Via Investor Brand Network
News headline image
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 ↗
Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an... 
Via MarketBeat
Topics Intellectual Property
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Canaccord Genuity Growth Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
CEO Michael Halstead to participate in a fireside chat on Wednesday, August 12 at 12:00 p.m. EDT 
From Helus Pharma
Via GlobeNewswire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Halstead as CEO
Via Investor Brand Network
News headline image
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Completes Enrollment in Phase 3 Depression Study
Via Investor Brand Network
Topics Intellectual Property
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data... 
Via FinancialNewsMedia
News headline image
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
From Helus Pharma
Via GlobeNewswire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
Via Investor Brand Network
News headline image
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
From Helus Pharma
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Closes $50 Million Public Offering
Via Investor Brand Network
News headline image
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Prices $50 Million Public Offering
Via Investor Brand Network
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial
Via Investor Brand Network
News headline image
FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
EQNX::TICKER_START (NASDAQ:HELP) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma™ Announces US$50 Million Underwritten Offering
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
From Helus Pharma
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Chief Medical Officer to Participate in H.C. Wainwright Neuro Perspectives Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Jefferies Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Issues Correction To TARA Mind Partnership Announcement
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.